New tyrosine kinase inhibitors in chronic myeloid leukemia
- PMID: 15820950
New tyrosine kinase inhibitors in chronic myeloid leukemia
Abstract
The deregulated activity of BCR-ABL tyrosine kinase originating from the t(9;22) chromosomal translocation has been shown to be necessary and sufficient for the transformed phenotype of chronic myeloid leukemia (CML) cells. This peculiarity has paved the way for the development of novel therapies specifically targeting the BCR-ABL gene product. The first BCR-ABL inhibitor to come into use in clinical practice, imatinib mesylate, is now the first-choice treatment for all newly diagnosed CML patients, but the initial striking efficacy of this drug has been overshadowed by the development of clinical resistance. The most common mechanisms of resistance include (i) BCR-ABL overexpression, and (ii) BCR-ABL kinase domain mutations disrupting critical contact points between imatinib and BCR-ABL or inducing a transition to a conformation to which imatinib is unable to bind. Several approaches to overcoming resistance have been studied both in vitro and in vivo. They include dose escalation of imatinib, the combination of imatinib with chemotherapeutic drugs, alternative BCR-ABL inhibitors, and inhibitors of kinases acting downstream of BCR-ABL such as Src kinases. Various novel tyrosine kinase inhibitors (TKI) have been synthesized and have now reached the pre-clinical or clinical phase. This review highlights the development of new TKI as specific molecularly targeted therapy and as the principal mechanisms for overcoming imatinib resistance.
Similar articles
-
Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).Crit Rev Oncol Hematol. 2006 Feb;57(2):145-64. doi: 10.1016/j.critrevonc.2005.06.007. Epub 2005 Oct 5. Crit Rev Oncol Hematol. 2006. PMID: 16213151 Review.
-
[Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].Cas Lek Cesk. 2006;145(5):377-82. Cas Lek Cesk. 2006. PMID: 16755775 Czech.
-
Important therapeutic targets in chronic myelogenous leukemia.Clin Cancer Res. 2007 Feb 15;13(4):1089-97. doi: 10.1158/1078-0432.CCR-06-2147. Clin Cancer Res. 2007. PMID: 17317816 Review.
-
[Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].Rinsho Byori. 2004 Feb;52(2):136-44. Rinsho Byori. 2004. PMID: 15027317 Review. Japanese.
-
Imatinib resistance in CML.Cancer Lett. 2009 Feb 8;274(1):1-9. doi: 10.1016/j.canlet.2008.06.003. Epub 2008 Jul 23. Cancer Lett. 2009. PMID: 18653275 Review.
Cited by
-
BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph+ chronic myeloid leukemia.Am J Hematol. 2022 Sep;97(9):1215-1225. doi: 10.1002/ajh.26650. Epub 2022 Jul 18. Am J Hematol. 2022. PMID: 35794848 Free PMC article.
-
Bioactive Lipids as Chronic Myeloid Leukemia's Potential Biomarkers for Disease Progression and Response to Tyrosine Kinase Inhibitors.Front Immunol. 2022 Apr 13;13:840173. doi: 10.3389/fimmu.2022.840173. eCollection 2022. Front Immunol. 2022. PMID: 35493444 Free PMC article.
-
Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions.Hemasphere. 2021 Feb 17;5(3):e536. doi: 10.1097/HS9.0000000000000536. eCollection 2021 Mar. Hemasphere. 2021. PMID: 33623882 Free PMC article. Review.
-
Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site.Leukemia. 2017 Nov;31(11):2388-2397. doi: 10.1038/leu.2017.245. Epub 2017 Jul 31. Leukemia. 2017. PMID: 28757617 Free PMC article.
-
Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML.Leuk Res. 2017 Aug;59:47-54. doi: 10.1016/j.leukres.2017.05.008. Epub 2017 May 12. Leuk Res. 2017. PMID: 28549238 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous